Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 7/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 3/20 | 0.39 |
| ▸ | IRS1 | P35568 | 2/20 | 0.39 |
| ▸ | GAB1 | Q13480 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5831943 | 0.94 | KMT2A (0.44) | KMT2AMEN1POLBKLKB1CTSB | |
| SCHEMBL5831400 | 0.91 | KMT2A (0.42) | KMT2AMEN1POLBKLKB1CTSB | |
| SCHEMBL5832057 | 0.87 | ALDH1A1 (0.43) | KMT2AMEN1POLBKLKB1CTSB | |
| SCHEMBL5831426 | 0.84 | KMT2A (0.45) | KMT2AMEN1POLBKLKB1CTSB | |
| SCHEMBL3251004 | 0.83 | HSD11B1 (0.40) | KMT2AMEN1POLBCA1MAPT | |
| SCHEMBL5831130 | 0.82 | HSD11B1 (0.37) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL3620291 | 0.81 | HSD11B1 (0.53) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL5831021 | 0.80 | ALDH1A1 (0.46) | KMT2AMEN1POLBKLKB1CTSB | |
| SCHEMBL6614777 | 0.79 | PFKFB3 (0.35) | KMT2AMEN1POLBMAPTALDH1A1 | |
| SCHEMBL5831036 | 0.78 | CCNC (0.52) | KMT2AMEN1POLBKLKB1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| US-7074788-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | CPT1A, HSD11B1, CES1 | KMT2A 2980/4885MEN1 903/4885POLB 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.